Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Biochim Biophys Acta Rev Cancer. 2018 Apr 25;1870(1):2–14. doi: 10.1016/j.bbcan.2018.04.009

Figure 2. Examples of genotype-driven metabolic reprogramming in cancer.

Figure 2

a. Non-small cell lung cancer (NSCLC) with concomitant mutations in KRAS and LKB1 use an unusual form of pyrimidine biosynthesis initiated by carbamoylphosphate synthetase-1 (CPS1). NSCLC with mutations in KRAS and p53 display glucose-dependent glutathione (GSH) biosynthesis. b. KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) requires MAPK signaling to regulate glucose flux into the hexosamine biosynthesis pathway (HBP) and non-oxidative pentose phosphate pathway (Non-Oxidative PPP). These pathways contribute to protein glycosylation and nucleic acid synthesis, respectively.